| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Paws Inc. is a Albany, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oxford PharmaGenesis is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Share Medical Center is committed to the development of our staff.
Arraystar is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.